PMID-40437949 – GLP-1RA Cancer Risk: Meta-Analysis of RCTs

Silverii GA et al. "Glucagon-like peptide-1 receptor agonists and risk of cancer: a meta-analysis of randomized controlled trials," Diabetes, Obesity and Metabolism, 2025.

Quick Reference

Property	Value
PMID	40437949
DOI	—
Year	2025
Journal	Diabetes, Obesity and Metabolism
Study Type	Meta-analysis
Evidence Level	I
Sample	50 RCTs pooled
Peptide(s) Studied	Semaglutide, Tirzepatide

Key Findings

Meta-analysis of 50 RCTs found no overall increase in cancer risk with GLP-1RA use
A thyroid cancer signal was noted, consistent with the known rodent C-cell concern, but absolute risk remains very low
No significant increase in pancreatic, breast, or colorectal cancer risk
The thyroid signal was driven primarily by longer-duration trials and may reflect detection bias (increased thyroid monitoring in GLP-1RA-treated patients)
Results were robust across sensitivity analyses excluding individual agents

Study Design

Meta-analysis of 50 randomized controlled trials reporting cancer-related adverse events in GLP-1RA-treated vs. control groups. Included all available GLP-1RA agents. Pre-specified subgroup analyses by cancer type, agent, and trial duration.

Limitations

Cancer events reported as adverse events rather than primary endpoints in most trials
Follow-up durations generally 1-3 years, insufficient for long-latency cancers
Thyroid cancer signal may reflect ascertainment bias
Individual cancer type analyses have limited statistical power due to rarity of events

Clinical Relevance

Provides further Level I evidence that GLP-1RAs do not meaningfully increase overall cancer risk. The thyroid signal is worth noting for patient counseling but must be contextualized with the very low absolute risk. Complements the larger Ko 2026 study (PMID-41359966) and addresses the same question from a slightly different trial pool. Supports continued use of semaglutide and tirzepatide with standard thyroid monitoring.

#research #meta-analysis #evidence-level-I #cancer